SCHEMBL1337890

SCHEMBL1337890

Nc1ccc(-c2cccc(OC3CC3)c2)cc1F

nearest known ligand 0.46

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 4/20 0.46
FFAR4 Q5NUL3 3/20 0.44
SLC6A2 P23975 3/20 0.42
SLC6A3 Q01959 3/20 0.42
SLC6A4 P31645 2/20 0.42
SLC16A3 O15427 1/20 0.38
SLC16A1 P53985 1/20 0.38
ENPP2 Q13822 1/20 0.38
TAAR1 Q96RJ0 1/20 0.38
FFAR1 O14842 1/20 0.37
NAAA Q02083 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1337675 0.86 DHODH (0.49) DHODHFFAR4SLC6A2SLC6A3SLC6A4
SCHEMBL1337871 0.82 SLC6A2 (0.50) DHODHFFAR4SLC6A2SLC6A3SLC6A4
SCHEMBL31508140 0.82 ALDH1A1 (0.43) FFAR4SLC6A2SLC6A3SLC6A4
SCHEMBL1336643 0.81 FFAR4 (0.51) DHODHFFAR4SLC6A2SLC6A3SLC6A4
SCHEMBL17027769 0.80 DHODH (0.47) DHODHFFAR4SLC6A2SLC6A3SLC6A4
SCHEMBL2595252 0.79 SLC6A2 (0.55) DHODHFFAR4SLC6A2SLC6A3SLC6A4
SCHEMBL1337887 0.78 MAOB (0.55)
SCHEMBL1336962 0.77 MAP4K4 (0.53) DHODHFFAR1
SCHEMBL16334746 0.77 FFAR4 (0.56) DHODHFFAR4SLC6A2SLC6A3SLC6A4
SCHEMBL22289350 0.76 PTGS1 (0.51) FFAR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2566847-B1 NOVEL IMMUNOMODULATOR AND ANTI INFLAMMATORY COMPOUNDS ICOZEN THERAPEUTICS PVT LTD (IN) 2018-11-07 EP disclosed
US-9758474-B2 Immunomodulator and anti-inflammatory compounds INCOZEN THERAPEUTICS PVT. LTD. (IN) 2017-09-12 US disclosed
US-20140220050-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS INCOZEN THERAPEUTICS PVT. LTD. (CH) 2014-08-07 US disclosed
US-20110275603-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS RHIZEN PHARMACEUTICALS SA (FR) 2011-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140220050-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS DHODH, DLD, DHFR DHODH 1/4885FFAR4 1678/4885SLC6A2 4033/4885
US-20110275603-A1 NOVEL IMMUNOMODULATOR AND ANTI-INFLAMMATORY COMPOUNDS DHODH, DLD, DHFR DHODH 1/4885FFAR4 1678/4885SLC6A2 4033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.